Rabeprazole

  • C18H21 N3O3S ( rabeprazole )
  • C18H20N3NaO3S ( rabeprazole · sodium salt)

A02BC04

  • Colorless crystals ( rabeprazole )
  • Colorless crystals ( rabeprazole sodium salt · )

Proton pump inhibitor Ulkustherapeutikum

An inhibitor of the proton- potassium pump

  • 359.44 g · mol -1 ( rabeprazole )
  • 381.42 g · mol -1 ( · rabeprazole sodium salt)
  • 99-100 ° C ( rabeprazole )
  • 140-141 ° C ( · rabeprazole sodium salt)

Slightly soluble in methanol and in water, soluble in ethanol, chloroform and ethyl acetate, insoluble in n-hexane and ether ( rabeprazole sodium salt · )

Template: Infobox chemical / molecular formula search available

Rabeprazole is a drug from the group of proton pump inhibitor that is used in the treatment of gastric and duodenal ulcers and in reflux oesophagitis.

  • 2.1 Mechanism of action ( pharmacodynamics )
  • 4.1 Chemical and pharmaceutical information 4.1.1 stereoisomerism

Clinical information

Indications / Applications

  • Treatment and prophylaxis of peptic gastric and duodenal ulcers
  • Reflux oesophagitis
  • Eradication of Helicobacter pylori ( along with two appropriate antibiotics )
  • Zollinger -Ellison syndrome

Pharmacological properties

Mechanism of action ( pharmacodynamics )

Rabeprazole acts as an inhibitor of H / K -ATPase. This leads to a reduction of the hydrochloric acid production in the stomach, and the pH value of the gastric juice increases. This leads to mitigation of the aggressiveness of gastric juice and thus to accelerated healing of gastric wall injury ( such as mucosal erosions or ulcers ).

Side effects

Like the other proton pump inhibitor rabeprazole also applies a relatively safe and is largely well tolerated. Common side effects include diarrhea, dizziness, fatigue and headaches.

Other Information

Chemical and pharmaceutical information

The multistep synthesis of rabeprazole is - described in the literature - starting from 2,3- dimethylpyridine.

Stereoisomerism

Rabeprazole has a chiral center at the sulfur atom, so it is chiral. The drug is a racemate, ie consists of a 1:1 mixture of ( R)-form and the mirror image ( S)-form.

Trade names

Pariet (D)

668317
de